Enabling happier and healthier lives.
Our vision
Humankind is still suffering from diseases that are considered incurable.
We design and discover medicines for these incurable diseases through event-driven pharmacology by exploiting AI to design proximity-inducing compounds (PICs™).
We envision a society where patients and physicians have precise control of pathogenic human protein concentrations via small molecules.
Our mission
Our mission is to bring multiple first-in-class small molecule PICs™ to market as drugs against hard-to-drug targets by 2035.
PICs™ induce proximity to cellular degradation machinery and require a deep understanding of chemistry and biology to be successfully developed. PICs™ are optimized for their physicochemical properties and offer distinct advantages for therapeutic development, such as oral bioavailability and permeability.
We developed our CelerisTx One™ platform to design such drugs and to rationally improve them in a closed-loop.
Our platform is a holistic solution to design the components necessary to induce protein proximity. CelerisTx One™ automates subsequent chemical and biological tasks before proceeding through multiple design-make-test iterations to develop medicines for high unmet medical needs.
Driven by people.
Team
DI Christopher Trummer
CEO, Co-Founder and President
Jakob Hohenberger
CFO/COO, Co-Founder and Director
Dr. Markus Müllner
CSO
Christopher Trummer
CEO and Co-Founder
Jakob Hohenberger
CFO/COO and Co-Founder
Dr. Markus Müllner
CSO
Noah Weber
CTO
Noah Weber
CTO
Alexandra Moik
Research Scientist
Dr. Arjun Rao
Senior ML Researcher
Dr. Oskar Hoff
Head of Medicinal Chemistry
Dr. Michael Brunsteiner
Principal Scientist Comp. Chemistry
Alexandra Moik
Dr. Arjun Rao
Dr. Oskar Hoff
Dr. Michael Brunsteiner
Dr. Honorine Lebraud
Business Development Manager
Chiara Gasbarri
Computational Chemist
Tatjana Hirschmugl
Scientific Illustrations and Arts
Dr. Sagar Gore
CADD Researcher
Dr. Honorine Lebraud
Chiara Gasbarri, MSc.
Tatjana Hirschmugl, MSc.
Dr. Sagar Gore
Sara Weiß
Finance and Operations
Tin Tunjic
ML Engineer
Dr. Alzbeta Tuerkova
Head of CADD
Christina Hetzmannseder
Research Scientist
Sara Weiß
Tin Tunjic
Dr. Alzbeta Tuerkova
Christina Hetzmannseder
Dr. Krisztian Gal
Project Manager
Dr. Sridhar Radhakrishnan
Medicinal Chemist
Dr. Krisztian Gal
Dr. Sridhar Radhakrishnan
Dr. Sagar Gore
Board of Directors
Marius Swart
Board Director
Karel Kubias
Board Director
Dr. Peter Ho
Board Director
Dr. Ronjon Nag
Board Observer and Advisor
Petr Sramek
Board Observer and Advisor
Marius Swart
Board Director
Karel Kubias
Board Director
Dr. Peter Ho
Board Director
Petr Sramek
Board Observer and Advisor
Dr. Ronjon Nag
Board Observer and Advisor
Scientific Advisory Board
Assoc.-Prof. Dr. Johannes Kirchmair
University of Vienna
Computational Drug Discovery & Design Group
Prof. Dr. Ola Spjuth
University of Uppsala
Pharmaceutical Biosciences and Bioinformatics
Prof. Dr. Jean-Louis Reymond
University of Bern
Chemistry and Drug Design
Prof. Dr. David Selwood
University College London
Biological and Medicinal Chemistry
Prof. Dr. Stefan Knapp
Goethe University Frankfurt
Pharmaceutical Chemistry
Assoc.-Prof. Dr. Johannes Kirchmair
University of Vienna
Computational Drug Discovery & Design Group
Prof. Dr. Ola Spjuth
University of Uppsala
Pharmaceutical Biosciences and Bioinformatics
Prof. Dr. Jean-Louis Reymond
University of Bern
Chemistry and Drug Design
Prof. Dr. David Selwood
University College London
Biological and Medicinal Chemistry
Prof. Dr. Stefan Knapp
Goethe University Frankfurt
Pharmaceutical Chemistry
